Publication Highlights Use of Ultrafiltration for Fluid Management in COVID-19 Patients
May 20 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced a publication highlighting the use of ultrafiltration for
fluid management of critically ill patients suffering from
COVID-19. “SARS-CoV-2 (COVID-19) and Intravascular Volume
Management Strategies in the Critically Ill”1 calls attention to
fluid stewardship in COVID-19 patients by judiciously applying the
evidence-based resuscitation principles to the specific clinical
features of COVID-19 patients.
“Fluid stewardship is likely to help reduce potential
complications in critically ill patients with COVID-19,” said Amir
Kazory, MD, FASN, FACC, a professor at the University of Florida,
and one of the publication’s authors. “The fact that a significant
subset of these patients suffers from rapidly expanding lung
lesions compromising their respiratory status makes it crucial to
prevent pulmonary congestion and, if iatrogenic fluid overload
develops, to efficiently treat it.”
Highlights of ultrafiltration identified in the publication
include:
- Isolated ultrafiltration is an optimal strategy that primarily
focuses on fluid extraction and optimization of volume status;
- Portable ultrafiltration devices could prove particularly
helpful because the extremely small extracorporeal volume (i.e. 35
ml) will help avoid potentially adverse hemodynamic impact in
critically ill COVID-19 patients, and the predictability of the
fluid extraction will make it more likely to achieve the precise
goal for the de-escalation process; and
- Rapid device deployment capability and ease of use of dedicated
ultrafiltration machines is helpful with the high number of
infected patients and limited resources
“We are pleased that this publication will generate awareness of
ultrafiltration as a solution in the treatment paradigm for
critically ill COVID-19 patients,” said John Erb, CEO of CHF
Solutions. “The Aquadex SmartFlow™ ultrafiltration system, with an
extracorporeal volume of 35ml, provides a simple, flexible and
smart solution for patients suffering from fluid overload due to
COVID-19 and other critical care conditions mentioned in the
publication.”
About CHF Solutions CHF Solutions, Inc.
(Nasdaq: CHFS) is a medical device company dedicated to improving
the lives of patients suffering from fluid overload with its novel
ultrafiltration therapy system. The company is focused on
developing, manufacturing and commercializing the Aquadex SmartFlow
system for ultrafiltration therapy. CHF Solutions is headquartered
in Minneapolis, Minn., with wholly-owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
ultrafiltration in COVID-19 patients. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our expectations regarding
the potential impacts of the COVID-19 pandemic on our business
operations, cash flow, business development, and employees, our
ability to execute on our commercial strategy, the possibility that
we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, , the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. CHF Solutions does not assume any obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
1. https://pubmed.ncbi.nlm.nih.gov/32336959/
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024